Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed‐Sternberg cells

The CD30 ligand (CD30L) and CD40L are members of the tumor necrosis factor (TNF) protein superfamily. CD30L and CD40L are mainly expressed as membrane‐bound proteins by activated T cells. CD30L and CD40L are costimulatory for T cell proliferation and activation. Further, CD40L is a critical signal for T cell‐dependent activation of B cells. Primary and cultured Hodgkin and Reed‐Sternberg (H‐RS) cells, the neoplastic component of Hodgkin's disease (HD), express high levels of the counterreceptors CD30 and CD40. We have found that both the recombinant CD30L and CD40L enhanced interleukin (IL)‐6, TNF and lymphotoxin (LT)‐α release from cultured H‐RS cells. In addition, CD40L, but not CD30L, induced IL‐8 secretion. CD30L and CD40L seem to share some redundant biological activities involved in the deregulated secretion of cytokines known to play a central role in the clinical presentation and pathology of HD. Further, CD30L enhanced surface expression of intercellular adhesion molecule‐1 (ICAM‐1/CD54) on cultured H‐RS cells, which is frequently overexpressed on primary H‐RS cells. CD30L‐ and CD40L‐enhanced CD54 surface expression is followed by elevated shedding of CD54, as shown by detection of elevated 82‐kDa soluble (s) CD54 levels in culture supernatants after stimulation with both ligands. CD30L and CD40L share common pleiotropic biological activities on CD30+/CD40+ H‐RS cells and are elements of the cytokine and cell contact‐dependent activation network typical for HD, a tumor of cytokine producing cells.

[1]  V. Diehl,et al.  Increased levels of circulating interleukin‐6 in patients with hodgkin's disease , 2006, Hematological oncology.

[2]  S. Dower,et al.  Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. , 1995, Blood.

[3]  V. Zagonel,et al.  Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. , 1995, Blood.

[4]  H. Drexler,et al.  Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. , 1994, Leukemia.

[5]  D. Hirschstein,et al.  Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease , 1994 .

[6]  M. Kadin.  Pathology of Hodgkin's disease , 1994, Current opinion in oncology.

[7]  R. Armitage.  Tumor necrosis factor receptor superfamily members and their ligands. , 1994, Current opinion in immunology.

[8]  N. Boiani,et al.  Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines , 1994 .

[9]  Terry Farrah,et al.  The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death , 1994, Cell.

[10]  J. Gribben,et al.  In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. , 1994, Blood.

[11]  C. Janeway,et al.  Induction of B cell costimulatory function by recombinant murine CD40 ligand , 1994, European journal of immunology.

[12]  G. Thomas,et al.  Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients , 1993, Cell.

[13]  C. Maliszewski,et al.  CD40L: a multi-functional ligand. , 1993, Seminars in immunology.

[14]  J. Delabie,et al.  The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines , 1993 .

[15]  F. Ramsdell,et al.  CD40 ligand is a T cell growth factor , 1993, European journal of immunology.

[16]  F. Herrmann,et al.  The significance of serum levels of soluble 60kDa receptors for tumor necrosis factor in patients with Hodgkin's disease. , 1993, Leukemia.

[17]  S. Pileri,et al.  Lymphotoxin, tumour necrosis factor and interleukin‐6 gene transcripts are present in Hodgkin and Reed‐Sternberg cells of most Hodgkin's disease cases , 1993, British journal of haematology.

[18]  F. Herrmann,et al.  Serum levels of circulating ICAM-1 are increased in Hodgkin's disease. , 1993, Leukemia.

[19]  N. Copeland,et al.  CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF , 1993, Cell.

[20]  R. Kurzrock,et al.  Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. , 1993, Cancer research.

[21]  M. Chilosi,et al.  ICAM‐1 tissue overexpression associated with increased serum levels of its soluble form in Hodgkin's disease , 1993, British journal of haematology.

[22]  T. Kipps,et al.  Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal , 1993, The Journal of experimental medicine.

[23]  R. Schwartz.  Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy , 1992, Cell.

[24]  V. Diehl,et al.  Expression of the novel intermediate filament-associated protein restin in Hodgkin's disease and anaplastic large-cell lymphoma. , 1992, Blood.

[25]  V. Diehl,et al.  Production of multiple cytokines by Hodgkin's disease derived cell lines , 1992, Hematological oncology.

[26]  H. Drexler.  Recent results on the biology of Hodgkin and Reed-Sternberg cells. I. Biopsy material. , 1992, Leukemia & lymphoma.

[27]  P. Banks,et al.  Hodgkin's disease. , 1992, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[28]  F. Herrmann,et al.  Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells. , 1992, Cancer research.

[29]  A. Gearing,et al.  Expression and cell distribution of the intercellular adhesion molecule, vascular cell adhesion molecule, endothelial leukocyte adhesion molecule, and endothelial cell adhesion molecule (CD31) in reactive human lymph nodes and in Hodgkin's disease. , 1992, The American journal of pathology.

[30]  K. Huebner,et al.  A novel IL‐1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. , 1991, The EMBO journal.

[31]  C. von Kalle,et al.  Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. , 1991, Blood.

[32]  S. Ziegler,et al.  Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes , 1991, The Journal of experimental medicine.

[33]  E. Clark,et al.  CD40 signaling activates CD11a/CD18 (LFA-1)-mediated adhesion in B cells. , 1991, Journal of immunology.

[34]  J. Gerdes,et al.  Tumor Necrosis Factor α and Lymphotoxin Production in Hodgkin's Disease , 1990 .

[35]  S. Pileri,et al.  BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. , 1989, Blood.

[36]  S. Poppema.  The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease. , 1989, The American journal of pathology.

[37]  R. Fisher,et al.  Immunology and cellular biology of Hodgkin's disease. , 1989, Hematology/oncology clinics of North America.

[38]  R. Rothlein,et al.  Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies. , 1988, Journal of immunology.

[39]  R. Fisher,et al.  Biochemical and structural properties of a Hodgkin's disease-related membrane protein. , 1988, Journal of immunology.

[40]  K. Lennert,et al.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. , 1985, Blood.

[41]  R. Fisher,et al.  Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells. , 1985, Journal of immunology.

[42]  V. Diehl,et al.  Identification of Hodgkin and sternberg‐reed cells as a unique cell type derived from a newly‐detected small‐cell population , 1982, International journal of cancer.

[43]  V. Diehl,et al.  Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells , 1982, Nature.

[44]  S. Howie,et al.  CD40 expression in Hodgkin's disease. , 1994, The American journal of pathology.

[45]  J. Banchereau,et al.  The CD40 antigen and its ligand. , 1994, Annual review of immunology.

[46]  F. Herrmann,et al.  Hodgkin's disease: a cytokine-producing tumor--a review. , 1994, Critical reviews in oncogenesis.

[47]  H. Drexler,et al.  Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. , 1993, Leukemia & lymphoma.

[48]  D. Parker.  T cell-dependent B cell activation. , 1993, Annual review of immunology.

[49]  H. Stein,et al.  Epstein-Barr virus and CD30+ malignant lymphomas. , 1993, Critical reviews in oncogenesis.

[50]  S. Akira,et al.  Biological and clinical aspects of interleukin 6. , 1990, Immunology today.